Dr. David Pearlstone from John Theurer Cancer Center Discusses Mammogram Deterrents
David Pearlstone, MD
Advertisement
Articles by David Pearlstone, MD
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.
David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years
David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Struggles Facing Breast Oncologists
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Genomics and Personalized Medicine
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on his Role in Designing new Equipment
Dr. David Pearlstone, from John Theurer Cancer Center, Describes the Young Cancer Coalition
Advertisement
Latest Updated Articles
Dr. Pearlstone Discusses Mammogram DeterrentsPublished: April 26th 2011 | Updated:
Dr. Pearlstone on Technological ChallengesPublished: March 8th 2011 | Updated:
Dr. Pearlstone on Ongoing Research in Breast CancerPublished: March 16th 2011 | Updated:
Dr. Pearlstone on Practice Changing StudiesPublished: March 8th 2011 | Updated:
Dr. Pearlstone on Difficult Patient ConversationsPublished: March 10th 2011 | Updated:
Dr. Pearlstone on Current Biomarker UtilizationPublished: March 10th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5